The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Preliminary interim results of the first-in-human, dose-finding PROCLAIM-CX-072 trial of the PD-L1 Probody therapeutic (Pb-Tx) CX-072 in combination with ipilimumab (ipi) in patients (pts) with advanced solid tumors.
 
Rachel E. Sanborn
Honoraria - AstraZeneca
Consulting or Advisory Role - Abbvie; Amgen; ARIAD; AstraZeneca; Celldex; Genentech/Roche; Peregrine Pharmaceuticals; Seagen; Takeda
Research Funding - Bristol-Myers Squibb (Inst); MedImmune (Inst); Merck
Travel, Accommodations, Expenses - Five Prime Therapeutics
 
Catharina Wilhelmina Menke
Research Funding - Cristal Therapeutics
 
Karen A. Autio
Research Funding - ARMO BioSciences (Inst); CytomX Therapeutics (Inst); GlaxoSmithKline (Inst); Merck (Inst); Pfizer (Inst)
 
Hendrik-Tobias Arkenau
No Relationships to Disclose
 
Javier Garcia Corbacho
No Relationships to Disclose
 
Patricia LoRusso
Leadership - Agios; Five Prime Therapeutics; Halozyme; Roche/Genentech
Honoraria - Genentech/Roche
Consulting or Advisory Role - Alexion Pharmaceuticals; ARIAD; CytomX Therapeutics; Genentech; Genentech; Genmab; Glenmark; Ignyta; Menarini; Novartis; Omniox; Takeda
Research Funding - Alexion Pharmaceuticals; Boehringer Ingelheim; Genentech (Inst); Immunogen (Inst); Merrimack (Inst); Novartis (Inst); Pfizer; Taiho Pharmaceutical (Inst); Tensha Therapeutics (Inst)
Travel, Accommodations, Expenses - Alexion Pharmaceuticals; Genentech/Roche
 
Elizabeth Ruth Plummer
Honoraria - Bristol-Myers Squibb; Pfizer (I); Roche/Genentech
Consulting or Advisory Role - Astex Pharmaceuticals; Bayer; Clovis Oncology; Modulatex; MSD Oncology; Novartis; Octimet; Pierre Fabre; Roche/Genentech; Vertex
Speakers' Bureau - Novartis
Research Funding - AstraZeneca/MedImmune (Inst)
Patents, Royalties, Other Intellectual Property - Named on patent of use of PARP inhibitor rucaparib (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD Oncology
 
Nataliya Volodymyrivna Uboha
Consulting or Advisory Role - EMD Serono; Flatiron Health; Gerson Lehrman Group
 
Morganna Louise Freeman
Consulting or Advisory Role - Amgen; Merck; Merck Serono; Novartis
Speakers' Bureau - Bristol-Myers Squibb
 
Jerzy Wydmanski
No Relationships to Disclose
 
Vanessa Huels
Employment - Abbvie (I); CytomX Therapeutics; Threshold Pharmaceuticals
Stock and Other Ownership Interests - Abbvie (I); CytomX Therapeutics; Threshold Pharmaceuticals
 
Beiyao Zheng
Employment - CytomX Therapeutics
 
Matthias Will
Employment - CytomX Therapeutics
 
Rachel W. Humphrey
Employment - CytomX Therapeutics
 
Fiona Thistlethwaite
Honoraria - Novartis
Consulting or Advisory Role - Achilles Therapeutics; Bristol-Myers Squibb; Bristol-Myers Squibb/Medarex; Evelo Therapeutics; Octimet (Inst); Pfizer
Speakers' Bureau - Bristol-Myers Squibb; Bristol-Myers Squibb
Research Funding - Aveo (Inst); GenMab (Inst); MedImmune (Inst); Novartis (Inst); Pfizer (Inst); Synthon (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; IPSEN
Other Relationship - Novartis; Pfizer
 
Elisabeth G.E. de Vries
Consulting or Advisory Role - Pfizer (Inst)
Research Funding - Amgen (Inst); AstraZeneca (Inst); Chugai Pharma (Inst); CytomX Therapeutics (Inst); Nordic Nanovector (Inst); Radius Health (Inst); Roche/Genentech (Inst); Synthon (Inst)
 
Anthony B. El-Khoueiry
Honoraria - Bayer; Bristol-Myers Squibb; Eisai; EMD Serono; Merck; Novartis; Roche/Genentech
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; CytomX Therapeutics; Eisai; EMD Serono; Merck; Roche
Research Funding - Astex Pharmaceuticals; AstraZeneca